CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,483 enrolled
Drug / intervention
Hydroxychloroquine +1 moredrug
Likely dose
Hydroxychloroquine 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04328467
NCT04328467Phase 3Completed
CompareCT.gov

Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial

University of Minnesota·interventional·Posted Mar 31, 2020·Updated Jul 2, 2021

In Brief

A Phase 3 clinical trial evaluating Hydroxychloroquine and Placebo for COVID-19 and 3 related conditions. Completed, enrolled 1,483 participants across 2 sites.

Detailed Summary

Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedMar 31, 2020
Enrollment StartApr 6, 2020
Primary CompletionJul 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.3 years ago

Interventions

Hydroxychloroquinedrug

Hydroxychloroquine; 200mg tablet; oral

Placeboother

Placebo; tablet; oral